ERBB2 and neoplasm: Pre-NAST tumor stage (cT4 vs. cT1-3, OR 0.15, 95% CI 0.03–0.63; p = 0.01), grading (G3 vs. G1–2, OR 2.19, 95% CI 1.12–4.28), tumor biology (HER2-positive vs. luminal HER2-negative, OR 8.94, 95% CI 4.02–19.89; p < 0.001; TNBC vs. luminal HER2-negative, OR 3.55, 95% CI 1.71–7.37, p < 0.001), and LPBC (yes vs. no, OR 3.39, 95% CI 1.29–8.96, p = 0.014) were further identified as independent predictors of pCR-LN.